A Phase II, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) With Pembrolizumab (KEYTRUDA®) for Recurrent Glioblastoma or Gliosarcoma (CAPTIVE/KEYNOTE-192)
Phase of Trial: Phase II
Latest Information Update: 01 Sep 2017
At a glance
- Drugs DNX 2401 (Primary) ; Pembrolizumab
- Indications Glioblastoma
- Focus Therapeutic Use
- Acronyms CAPTIVE
- Sponsors DNAtrix
- 01 Nov 2016 According to a DNAtrix media release, first patient has been treated in this trial.
- 28 Jun 2016 Status changed from active, no longer recruiting to recruiting.
- 13 Jun 2016 Status changed from planning to active, no longer recruiting.